{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"ENPAC","nct_id":"NCT02684227","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=enpac-nct02684227. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.","label":"Treatment (enzalutamide, paclitaxel, carboplatin)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2023-09-27","type":"ACTUAL"},"conditions":["Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Uterine Corpus Carcinoma","Stage III Uterine Corpus Cancer AJCC v7","Stage IIIA Uterine Corpus Cancer AJCC v7","Stage IIIB Uterine Corpus Cancer AJCC v7","Stage IIIC Uterine Corpus Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Stage IVA Uterine Corpus Cancer AJCC v7","Stage IVB Uterine Corpus Cancer AJCC v7"],"enrollment":{"count":50,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["ASP9785","MDV3100","Xtandi"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"},{"name":"Pharmacological Study","otherNames":[],"type":"OTHER"}],"last_update":"2025-03-19","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)).","timeFrame":"up to 6.4 years"},{"measure":"To Determine the Safety and Feasibility of Daily Enzalutamide Given in Combination With Carboplatin and Paclitaxel in Women With Advanced Stage or Recurrent Endometrial Cancer","timeFrame":"up to 6.4 years"},{"measure":"Median Duration of Progression-free Survival","timeFrame":"up to 6.4 years"}],"references":[],"start_date":{"date":"2016-08-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer","url":"https://clinicaltrials.gov/study/NCT02684227"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/enpac-nct02684227"}